RT期刊文章SR电子T1量化脑脊液神经损伤的生物标志物,在抗体介入神经炎症和突触完整脑炎(p2.2 - 001)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP p2.2 - 001签证官92天15 A1格雷戈里补充A1法蒂玛Amtashar A1梅勒妮Yarbrough A1彼得Koertvelyess首页y A1哈拉尔德Pruss A1罗伯特Bucelli A1马文fritzl A1沃伦·梅森A1大卫Tang-Wai A1克劳德Steriade A1朱利安赫伯特A1伊丽莎白掠夺A1杰克Ladenson A1约翰·c·莫里斯A1安妮·费根年2019 UL //www.ez-admanager.com/content/92/15_supplement/p2.2 - 001. -文摘AB目的:测定脑脊液(CSF)神经损伤的生物标志物,神经炎症和突触完整抗体介入脑炎患者(AME)。背景:恢复AME患者经常表现出持久的损害在内存和执行功能。生物标志物,通知贡献者长期认知后遗症需要识别高危病人的长期赤字。设计/方法:收集脑脊液从46名患者在诊断时NMDAR (n = 35)或LGI1 / CASPR-2 (n = 11) AME, 40岁,gender-similar认知正常志愿者评估在圣路易斯华盛顿大学(美国);多伦多大学,有丝分裂原诊断/卡尔加里大学(加拿大);或者查利特医院以及大学医院马格德堡(德国)。神经损伤的生物标志物(总τ,VILIP-1),炎症(YKL-40)和突触完整(neurogranin SNAP-25)病人和对照组之间比较,控制年龄(单变量ANCOVA)。结果:NMDAR脑炎患者年轻(平均26年;范围内,4.0 - -41.8)比患者LGI1 / CASPR2 AME(70.4年,60.6 - -83.2;p < 0.001)。神经损伤的标志相似(平均总τ(95%置信区间):22.4 pg / ml (16.3 - -28.5);与20.2 pg / ml (13.7 - -26.8); p=0.63) or decreased (VILIP-1: 42.5 pg/ml [31.4–53.6]; vs. 119.0 pg/ml [107.0–130.9]; p<0.001) in patients versus controls. The neuroinflammatory biomarker YKL-40 was elevated in patients compared to controls (YKL-40: 303.0 pg/ml [257.1–348.9] vs. 162.1 ng/ml [113.4–210.8]; p<0.001), while markers of synaptic integrity were decreased (SNAP-25: 1.54 pg/ml [1.19–1.89] vs. 3.20 pg/ml [2.83–3.58], p<0.001; neurogranin: 577.5 pg/ml [336.3–818.7] vs. 1462.9 pg/ml [1204.2–1721.7]; p<0.001). VILIP-1 levels differentiated patients with NMDAR (27.0 pg/ml [12.9–41.1]) from LGI1/CASPR2 AME (84.5 pg/ml [47.1–121.8]; p=0.02). No other biomarker differences were observed between patients.Conclusions: Cerebrospinal fluid biomarkers suggest that neuronal integrity is acutely maintained in AME patients. Low-levels of biomarkers of synaptic integrity may reflect antibody-mediated internalization of cell-surface receptors, and may represent an acute correlate of antibody-mediated synaptic dysfunction underlying cognitive sequelae in recovering patients.Disclosure: Dr. Day has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with DynaMed (EBSCO Health).Dr. Day holds stock and/or stock options in ANI Pharmaceuticals. Dr. Amtashar has nothing to disclose. Dr. Yarbrough has nothing to disclose. Dr. Körtvelyessy has nothing to disclose. Dr. Pruss has nothing to disclose. Dr. Bucelli has nothing to disclose. Dr. Fritzler has nothing to disclose. Dr. Mason has nothing to disclose. Dr. Tang-Wai has nothing to disclose. Dr. Steriade has nothing to disclose. Dr. Hebert has nothing to disclose. Dr. Herries has nothing to disclose. Dr. Ladenson has nothing to disclose. Dr. Morris has received research support from Eli Lilly and Biogen. Dr. Fagan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche Diagnostics, IBL International, AbbVie, Biogen, DiamiR, LabCorp and Araclon Biotech/Griffols.